BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25726878)

  • 1. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
    Lang-Lazdunski L; Bille A; Papa S; Marshall S; Lal R; Galeone C; Landau D; Steele J; Spicer J
    J Thorac Cardiovasc Surg; 2015 Feb; 149(2):558-65; discussion 565-6. PubMed ID: 25726878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.
    Lang-Lazdunski L; Bille A; Belcher E; Cane P; Landau D; Steele J; Taylor H; Spicer J
    J Thorac Oncol; 2011 Oct; 6(10):1746-52. PubMed ID: 21876457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
    Lang-Lazdunski L; Bille A; Lal R; Cane P; McLean E; Landau D; Steele J; Spicer J
    J Thorac Oncol; 2012 Apr; 7(4):737-43. PubMed ID: 22425923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
    Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
    Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
    Sugarbaker DJ; Gill RR; Yeap BY; Wolf AS; DaSilva MC; Baldini EH; Bueno R; Richards WG
    J Thorac Cardiovasc Surg; 2013 Apr; 145(4):955-963. PubMed ID: 23434448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
    J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Povidone iodine: the new solution for mesothelioma?
    Rusch VW
    J Thorac Cardiovasc Surg; 2015 Feb; 149(2):567-8. PubMed ID: 25467371
    [No Abstract]   [Full Text] [Related]  

  • 9. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
    Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
    Ishibashi H; Kobayashi M; Takasaki C; Okubo K
    Gen Thorac Cardiovasc Surg; 2015 Jul; 63(7):395-400. PubMed ID: 25750109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals.
    Bille A; Belcher E; Raubenheimer H; Landau D; Cane P; Spicer J; Lang-Lazdunski L
    Gen Thorac Cardiovasc Surg; 2012 May; 60(5):289-96. PubMed ID: 22453539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
    Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
    J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
    Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
    J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical indications and results after chest wall resection for recurrent mesothelioma.
    Burt BM; Ali SO; DaSilva MC; Yeap BY; Richards WG; Baldini EH; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1373-9; discussion 1379-80. PubMed ID: 24113019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
    Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
    Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
    Minatel E; Trovo M; Bearz A; Di Maso M; Baresic T; Drigo A; Barresi L; Furlan C; Del Conte A; Bruschi G; Fontana P; Pagan V; Franchin G
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):606-13. PubMed ID: 26281826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
    Nakas A; Waller D
    Eur J Cardiothorac Surg; 2014 Sep; 46(3):380-5; discussion 385. PubMed ID: 24482386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
    Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
    Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
    Nakamura A; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Matsumoto S; Kondo N; Kijima T; Yamakado K; Hasegawa S
    Ann Thorac Surg; 2020 May; 109(5):1537-1543. PubMed ID: 31962118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.